The US Food and Drug Administration (FDA) is set to discuss easing restrictions on certain research peptides, a class of drugs with limited evidence of human safety and efficacy, during a committee meeting scheduled for July 23-24. The move could effectively legalize a thriving gray market where these injectable substances are currently sold as wellness aids without regulatory oversight.
What Are Peptides and Why Are They Popular?
Peptides are short-chain amino acids that include both blockbuster drugs like GLP-1 weight loss medications and older drugs such as insulin. However, a raft of injectable “research” peptides not intended for human consumption are sold online, promoted by social media influencers and figures like Joe Rogan. These products are often produced by gray market compounding pharmacies, many based in China, and used by individuals seeking to “get ahead of things like age, weight loss, muscular dystrophy,” according to Mohammed Chammout, a retail pharmacist in Michigan.
“There are a lot of patients who are foaming at the mouth waiting for these peptides to get moved to Category 1 legal status,” Chammout said.
Safety Concerns and Lack of Evidence
Evidence of human safety and efficacy for peptides such as Semax and BPC-157 ranges from thin to nonexistent. Dr. Eric Topol, director of the Scripps Research Translational Institute, stated, “The ban is appropriate for these peptides that have no data and all sorts of concerns regarding safety.” Topol has been a vocal critic of the untested drugs.
BPC-157, sometimes called the “wolverine peptide,” is marketed for injury recovery and has shown positive results in animal studies, but the research was primarily conducted by one group in Croatia. Dr. Flynn McGuire, who studied the research, told Stat and Undark in 2025 that BPC-157 “should not be used by humans.” Consumer advocacy group Public Citizen has called for full FDA approval rather than a lenient workaround.
The FDA Advisory Committee Meeting
The FDA’s pharmacy compounding advisory committee will discuss seven peptides: BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, and Epitalon. The committee has three voting members, six vacancies, and one non-voting member from the pharmaceutical industry. While the FDA is not bound to follow the committee’s advice, it typically does.
If restrictions are eased, US compounding pharmacies could produce and fill prescriptions for these peptides, effectively legalizing the gray market. However, the drugs would not receive FDA approval, which requires years of phased clinical trials. Most drugs fail these rigorous trials.
Industry Push and Political Context
The push for change follows a 2023 Biden administration ban on compounding pharmacies producing 19 research peptides due to safety risks, including priapism and tumor growth. US Health Secretary Robert F. Kennedy Jr. recently called the ban “illegal” on The Joe Rogan Experience. Kennedy is a self-described “big fan” of peptides and has used them himself.
Wall Street analysts estimate that telehealth peptide prescribing could reach $2.2 billion per year, with Hims & Hers potentially capturing up to $440 million if restrictions are eased. Dr. Anant Vinjamoori, chief medical officer of Hims, said, “The evidence base is still developing, which is true of many treatments that are now standard of care.” However, he declined to identify a specific standard of care.
Critics worry the regulatory change is a fait accompli, pointing to Kennedy’s efforts to reduce childhood vaccines. In June 2025, he fired all 17 members of a federal vaccine advisory committee and replaced them with ideological allies, leading to a court blocking proposed changes. “Whatever RFK is pushing for will somehow get done,” Topol said.
